Compounded
Semaglutide
Any prescribed dose up to 2.5 mg/week
Prescription & clinician review included
Shipping included
$948 due today
Back to All Reviews
Investigation Report
Trava Tirzepatide Review
Trava, taketrava.com, Take Trava
Also spelled as Trava, taketrava.com, Take Trava — Same brand, same great service!
Our investigation of Compounded Tirzepatide from Trava
Caution Advised
Multiple red flags identified
Caution Advised
GLP-1s advertised from about $118/month all-inclusive, with quarterly packages saving roughly $88 to $95
100+
Hours Researched
8
Verified Pros
8
Issues Found
7
Final Score
These are Med Consumer Watch products, not products from Trava, the brand being reviewed on this page.
Med Consumer Watch GLP-1 plans
GLP-1 weight loss.
A brand on your side.
Med Consumer Watch exists to help consumers make informed choices. Our brand brings that mission to GLP-1 care: clear plan prices, clinician review and support included, so you can compare your options and get started with confidence.
Why choose Med Consumer Watch?
Know your full price
Medication, clinician review and shipping are included. See your total before you buy.
Same price at every included dose
Your plan price stays the same across its included prescribed doses. Choose 1, 3, 6 or 12 months.
Support beyond your prescription
Ongoing doctor messaging, health coaching and patient community access are included with your plan.
Choose your medication and the plan length that works for you.
Buy semaglutide
Compounded
Tirzepatide
Any prescribed dose up to 15 mg/week
Prescription & clinician review included
Shipping included
$1,548 due today
Treatment requires a prescription and clinician approval. If treatment is declined, your payment is refunded. Compounded medications are not FDA-approved.
Investigation Overview
Trava is one of the cheapest routes to a compounded GLP-1 we have found, and it gets the regulatory disclosure right in every place except the one a customer reads first. Our research (September 1, 2026) found a telehealth operation whose fine print is accurate and whose headline is not.
The Disclaimer Is Correct Where It Appears
Trava's FAQ answers the question directly and properly:"Are the medications FDA-approved? Compounded medications are not FDA-approved, but they are prepared in state-licensed pharmacies that follow USP safety and sterility standards. They are only prescribed when a licensed clinician determines they represent a meaningful option for your specific situation."Its footnote goes further:
"*Compounded medications are available by prescription only. They are not FDA approved and have not been evaluated for safety and effectiveness by the FDA. Trava works with state-licensed pharmacies..."Both are exactly right, and the FAQ answer is better than most — it does not merely disclaim, it explains the USP standards that do apply and frames prescribing as conditional on clinical judgement.
And Then the Headline Says This
"GLP-1's As Low as $118 tested in FDA approved labs"
"Quality tested in the USA by FDA labs"This is the problem. Those two phrases sit at the top of the page, immediately adjacent to the price, which is precisely where a customer forms their impression of regulatory status. "FDA approved labs" and "FDA labs" are not meaningful descriptions of anything in this supply chain — the FDA does not run the testing laboratories used by compounding pharmacies, and laboratory registration confers nothing on the drug product. A reader encountering "GLP-1's as low as $118 tested in FDA approved labs" will reasonably come away believing there is FDA endorsement attached to the medication, which the company's own FAQ correctly says there is not. We do not read this as deliberate deception, precisely because the accurate disclosure appears elsewhere on the same site. But a correct footnote does not neutralise an incorrect headline. The headline is what gets read.
Pricing Is Genuinely Low and Genuinely All-Inclusive
Trava advertises GLP-1s starting at $118, with a monthly figure of $117.96 on one plan and $178.98 on another, plus quarterly packages saving roughly $88 to $95. A range of other treatments run from about $69.98 to $178.98."Our all-inclusive pricing covers ongoing shipments, the medical visit, and seamless provider messaging, all bundled into one affordable and low price. No hidden fees or complexities."
"There's no upfront payment required to get started."No insurance is accepted or required. The intake takes about ten minutes and the consultation is included.
Clinical Process
"Licensed and board-certified providers review every intake. Our compounded medications are produced in U.S. facilities that meet strict USP standards."
"After completing your online intake, a licensed clinician reviews your health history and goals. If treatment is appropriate, they issue a prescription through our network of state-licensed, USP-compliant pharmacies."Prescribing is conditional, the pharmacies are described as state-licensed and USP-compliant, and no payment is required to begin — all of which is the right structure. The standard post-shortage caveat applies: with the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, lawful 503A compounding turns on a documented clinical reason for the individual patient. Worth asking about.
What Is Not Published
No pharmacy is named, and no 503A or 503B status is given — only "state-licensed" and "USP-compliant." No BMI or eligibility criteria. No lab requirements, titration protocol or monitoring schedule. No dose-tier structure, so what a maintenance dose costs is unclear. And no founding year, headquarters, named clinicians, refund terms or cancellation policy.Our Investigation Summary
Our research (September 1, 2026) found Trava offering compounded GLP-1 medications at among the lowest prices in this comparison — advertised from $118, with plan figures of $117.96 and $178.98 monthly and quarterly packages saving roughly $88 to $95 — under an all-inclusive model covering ongoing shipments, the medical visit and provider messaging, with no upfront payment required to begin and no insurance accepted or required. Its regulatory disclosure is a study in contrasts. The FAQ answers "Are the medications FDA-approved?" correctly and well: compounded medications are not FDA-approved, they are prepared in state-licensed pharmacies following USP safety and sterility standards, and they are prescribed only when a licensed clinician determines they are a meaningful option. A footnote adds that compounded medications are not FDA approved and have not been evaluated for safety and effectiveness by the FDA. Both statements are accurate. However, the site's headline marketing reads "GLP-1's As Low as $118 tested in FDA approved labs" and "Quality tested in the USA by FDA labs," positioned directly beside the price. Neither phrase describes anything meaningful — the FDA does not operate the testing laboratories used by compounding pharmacies, and no laboratory registration confers approval on a drug product — and their placement at the point where a customer assesses regulatory status invites exactly the inference the company's own FAQ contradicts. We do not read this as deliberate, given the accurate disclosure elsewhere on the same site, but a correct footnote does not cure an incorrect headline. Clinical process is otherwise sound: licensed and board-certified providers review every intake, medications are described as produced in US facilities meeting strict USP standards and dispensed through a network of state-licensed, USP-compliant pharmacies, and prescribing is conditional on the clinician finding treatment appropriate. Not published: any named pharmacy or its 503A/503B status, BMI or clinical eligibility criteria, lab requirements, titration protocols, monitoring schedules, dose-tier pricing showing maintenance-dose cost, founding year, headquarters, named clinicians, refund terms or cancellation policy.
How Trava Works
1
Complete an online intake, described as taking about ten minutes
2
No upfront payment is required to get started; the consultation is included
3
A licensed, board-certified clinician reviews your health history and goals
4
A prescription is issued only if the clinician finds treatment appropriate
5
Medication is compounded by a state-licensed, USP-compliant pharmacy
6
All-inclusive pricing covers shipments, the medical visit and provider messaging
7
Ask which pharmacy fills your prescription and under which pathway
8
Treat 'tested in FDA approved labs' as marketing, not regulatory status
What We Found
What's Good
- Among the lowest advertised GLP-1 prices in this comparison, from about $118/month
- FAQ answers the FDA-approval question correctly and explains USP standards
- Footnote states clearly that compounded medications are not FDA approved or evaluated
- No upfront payment required to start; consultation included
- Prescribing conditional on a clinician finding treatment appropriate
- All-inclusive pricing covering shipments, medical visit and provider messaging
- Licensed and board-certified providers review every intake
- Quarterly packages reduce the effective monthly cost
Watch Out For
- Headline claims 'tested in FDA approved labs' and 'FDA labs' on a compounded product
- That language sits beside the price, where regulatory impressions are formed
- No pharmacy named and no 503A/503B status disclosed
- No dose-tier pricing, so maintenance-dose cost is unknown
- No BMI or eligibility criteria published
- No lab requirements, titration protocol or monitoring schedule
- No refund terms or cancellation policy published
- No founding year, headquarters or named clinicians
Pricing Breakdown
Starting Price
GLP-1s advertised from $118/month, with plan figures of $117.96 and $178.98 monthly
Medication Cost
Included. Trava describes all-inclusive pricing covering ongoing shipments, the medical visit and provider messaging in one price
Subscription Fees
No separate membership fee identified. Quarterly packages are offered, saving roughly $88 to $95 against monthly billing. No insurance is accepted or required
Hidden Fees
None identified in published terms, and no upfront payment is required to start. However, no dose-tier structure is published, so the cost at a maintenance dose is not established
Safety & Medical Oversight
Trava's clinical process is described appropriately: licensed and board-certified providers review every intake, a clinician reviews health history and goals before any prescription is issued, and a prescription follows only "if treatment is appropriate," with medications produced in US facilities described as meeting strict USP standards and dispensed through a network of state-licensed, USP-compliant pharmacies. Its FAQ handles the central regulatory question correctly, stating that compounded medications are not FDA-approved while explaining the USP safety and sterility standards that do apply, and a site footnote states plainly that compounded medications are not FDA approved and have not been evaluated for safety and effectiveness by the FDA. Against that, the site's headline marketing describes GLP-1s as "tested in FDA approved labs" and "Quality tested in the USA by FDA labs." These phrases have no substantive meaning in this supply chain: the FDA does not operate the analytical laboratories used by compounding pharmacies, and laboratory registration or inspection status does not confer approval, safety review or efficacy review on a compounded drug product. Placed adjacent to the price at the top of the page, that language is positioned exactly where a patient forms a view on regulatory status, and it points the opposite way from the company's own accurate FAQ. Patients should rely on the FAQ and footnote, not the headline. Sourcing detail is thin: no pharmacy is named and no 503A or 503B pathway is disclosed, which matters because following resolution of the tirzepatide shortage in October 2024 and semaglutide in early 2025, lawful patient-specific compounding depends on a documented clinical rationale rather than a shortage. What we could not establish: BMI or clinical eligibility thresholds, whether laboratory work is required before prescribing, the titration protocol used, the monitoring schedule after prescribing, and the credentials of specific clinicians. GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumours and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Customer Support
Trava describes itself as providing "structured, accountable care with real human support at every stage," with seamless provider messaging bundled into the all-inclusive price rather than sold as a premium tier. The entry path is designed to reduce commitment risk: intake takes roughly ten minutes, the medical consultation is included, and the company states there is no upfront payment required to get started, so a patient reaches a clinical decision before paying. Direct pharmacy oversight is claimed as part of the model, and medication is shipped directly to the patient. No insurance is accepted, which Trava frames as enabling simpler pricing. What we found no published information on: telephone support, support hours, response-time commitments for provider messaging, the cadence of follow-up contact after a prescription is issued, the cancellation procedure, or refund terms — the latter being a notable omission for a recurring subscription with quarterly prepay options.
Key Features
GLP-1s from $118/mo
All-Inclusive Pricing
No Upfront Payment
Consultation Included
Board-Certified Review
USP-Compliant Pharmacies
Quarterly Package Savings
Provider Messaging Included
Best For
Price-sensitive patients who will read the FAQ rather than the headline, and who accept compounded medication from an unnamed pharmacy in exchange for among the lowest pricing in the category
Customer Reviews & Complaints
We assessed Trava against its published material as of September 1, 2026.
What we verified directly: GLP-1s advertised from $118 with plan figures of $117.96 and $178.98 monthly and quarterly packages saving roughly $88 to $95; all-inclusive pricing covering shipments, medical visit and provider messaging; no upfront payment to begin; intake reviewed by licensed, board-certified providers; medications described as produced in US facilities meeting USP standards and dispensed by state-licensed, USP-compliant pharmacies; an FAQ correctly stating compounded medications are not FDA-approved; a footnote stating they have not been evaluated for safety and effectiveness by the FDA; and headline copy reading "tested in FDA approved labs" and "Quality tested in the USA by FDA labs."
The contradiction between the headline and the FAQ is the central finding. Both statements are on the same website. One is accurate and one is not, and the inaccurate one is in larger type, higher on the page, next to the price.
To be fair to Trava, the accurate disclosure is real and it is good. The FAQ answer does not just disclaim — it explains what USP standards mean and frames prescribing as a clinical judgement. That is better than many competitors manage anywhere on their sites. This looks like marketing copy written separately from compliance copy, rather than an attempt to mislead.
But the headline is what gets read. A patient who reads only the hero section comes away with a materially wrong belief about the regulatory status of what they are buying, and the price is right there to act on.
The commercial terms are otherwise patient-friendly. No upfront payment, consultation included, all-inclusive pricing, and a clinical decision before money changes hands is a better structure than several higher-rated competitors offer.
What we could not establish: the pharmacy and its 503A/503B status, dose-tier pricing, eligibility criteria, lab requirements, titration protocols, monitoring cadence, refund and cancellation terms, founding year, headquarters, or independent third-party review aggregates.
Is Trava Legit?
"Is Trava legit?" Our assessment as of September 1, 2026.
Official Verification: Trava presents as a clinician-guided telehealth company for weight loss, metabolic health and longevity, using licensed and board-certified providers and a network of state-licensed, USP-compliant compounding pharmacies. Its FAQ and footnotes carry accurate statements about the regulatory status of compounded medication. We found no evidence of wrongdoing.
The commercial structure is sound. No upfront payment, an included consultation, and a prescription issued only if a clinician finds treatment appropriate means the clinical decision precedes the financial one — the opposite of the pay-then-qualify pattern we flag at Healthy Living Clinic.
The headline language is the reason this is not rated higher. "Tested in FDA approved labs" and "Quality tested in the USA by FDA labs" attach the FDA's name to a product the FDA has not approved, in the position on the page where a customer decides what they are buying. The FDA does not operate these laboratories, and no laboratory's status makes a compounded drug FDA-approved. The company's own FAQ says as much.
How to read it. Trust the FAQ and the footnote; disregard the hero copy. If you want a provider that does not create this tension in the first place, NexLife attaches its compounding correction directly to its efficacy claims, and Raeliva states that cited trial data does not describe its products at all.
Red Flags Check:
- ✓ FAQ states correctly that compounded medications are not FDA-approved
- ✓ Footnote states they have not been evaluated for safety or effectiveness by the FDA
- ✓ Explains the USP safety and sterility standards that do apply
- ✓ No upfront payment; clinical decision precedes payment
- ✓ Prescribing conditional on clinician assessment
- ✓ Licensed, board-certified providers review every intake
- ⚠ Headline reads 'tested in FDA approved labs' beside the price
- ⚠ 'Quality tested in the USA by FDA labs' implies approval that does not exist
- ⚠ No pharmacy named; 503A/503B status undisclosed
- ⚠ No dose-tier pricing; maintenance-dose cost unknown
- ⚠ No BMI criteria, lab requirements, titration protocol or monitoring schedule
- ⚠ No refund or cancellation terms published
The Bottom Line: Cheap, structurally fair on payment, and accurate everywhere except the headline — where it attaches the FDA's name to a compounded drug the FDA has not approved. If you use Trava, understand that you are buying a compounded medication with no FDA review, whatever the hero copy suggests, and ask which pharmacy compounds it and what a maintenance dose costs. As always, consult your personal physician before starting any new medication program.
Our Verdict: Caution Advised
Trava has a 7/10 site score. We've identified some concerns that potential customers should be aware of. We recommend reviewing our top picks before proceeding.
Visit TravaTrava
Caution Advised
7/10
GLP-1s advertised from about $118/month all-inclusive, with quarterly packages saving roughly $88 to $95
Prescription treatment requires clinician review
Investigation Summary
Overall Rank#205 of 226
Rating7/10
StatusCaution Advised
PricingGLP-1s advertised from about $118/month all-inclusive, with quarterly packages saving roughly $88 to $95
Want to compare options?
View All 226 ProvidersUser Reviews
Rating Summary
No ratings yet
Rate your experience
Click a star to rate and add a review
Questions & Discussions
226 Providers Reviewed
Explore Other Reviews
Compare with other GLP-1 weight loss providers we've investigated
Our Top Picks
#1 RecommendedExcellent
#2 RecommendedExcellent
#3 RecommendedExcellent
More Provider Reviews
CoreAge Rx
9.9
SuperHealthy Rx
9.7
Likeness Rx
9.5
Mochi Health
8.8
Remedy Meds
8.3
Caution Advised
Ready to Get Started with Trava?
Review our findings above and make an informed decision about Trava.
Enter to Win a $1,788 CoreAge Rx Gift Card
Enter for a chance to use it toward eligible CoreAge Rx products and services.
The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.